Showing results (111-120 of 176) with videos related to

Sort By:
Pageof 18
Journal of Public Health (Oxford, England)|November 23, 2007
Can syndromic thresholds provide early warning of national influenza outbreaks?D L Cooper, N Q Verlander, A J Elliot, et al.
Journal of Wound Care|September 10, 2016
Thermal territories of the abdomen after caesarean section birth: infrared thermography and analysisC Childs, M R Siraj, F J Fair, et al.
The Journal of Organic Chemistry|June 9, 2016
Automated Glycan Assembly of Complex Oligosaccharides Related to Blood Group DeterminantsHeung Sik Hahm, Chien-Fu Liang, Chian-Hui Lai, et al.
The Journal of Infection|June 22, 2007
The contribution of respiratory pathogens to the seasonality of NHS Direct callsD L Cooper, G E Smith, W J Edmunds, et al.
Clinics in Laboratory Medicine|December 1, 1995
Enzymatic and molecular diagnosis of Gaucher diseaseJ A Barranger, E Rice, S A Sakallah, et al.
Experimental Cell Research|March 30, 1999
Alternatively spliced CD44 isoforms containing exon v10 promote cellular adhesion through the recognition of chondroitin sulfate-modified CD44R K Chiu, A Droll, S T Dougherty, et al.
Communicable Disease and Public Health|August 9, 2002
Use of NHS Direct calls for surveillance of influenza--a second year's experienceD L Cooper, G E Smith, V A Hollyoak, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 2, 2013
Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographicsA L Forsyth, M Gregory, D Nugent, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 21, 2013
Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registriesA D Shapiro, E J Neufeld, V Blanchette, et al.
Cancer Investigation|April 1, 1999
Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiationE Salloum, L T Tanoue, F J Wackers, et al.
Pageof 18